Ciplet 
(Ciprofloxacin)
Composition: 
Ciplet 250mg film coated tablet containing 291mg ciprofloxacin hydrochloride monohydrate U.S.P. (equivalent to 250mg ciprofloxacin). 
Ciplet 500mg film coated tablet containing 583mg ciprofloxacin hydrochloride monohydrate U.S.P. (equivalent to 500mg ciprofloxacin). 
Ciplet I.V. 200mg/100ml (ciprofloxacin) is a synthetic broad-spectrum antimicrobial agent for intravenous (I.V.) administration 
Description: 
Ciplet I.V. infusion (ciprofloxacin) is a synthetic broad spectrum antibacterial agent for Intravenous (I.V.) administration 
Indications: 
Ciplet I.V. is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. 
Adult Patients 

Urinary Tract Infections: caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae subspecies pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri,Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 

Lower Respiratory Infections: caused by Escherichia coli, Klebsiella pneumoniae subspecies pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilusinfluenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also,Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. 

Nosocomial Pneumonia: caused by Haemophilus influenzae or Klebsiella pneumoniae. 
Skin and Skin Structure Infections: caused by Escherichia coli, Klebsiella pneumoniae subspecies pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 
Bone and Joint Infections: caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas, aeruginosa. 

Complicated Intra-Abdominal Infections:(used in conjunction with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Acute Sinusitis: caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. 

Chronic Bacterial Prostatitis: caused by Escherichia coli or Proteus mirabilis. 
Empirical Therapy for Febrile Neutropenic Patients: in combination with piperacillin sodium. 
Pediatric patients: (1 to 17 years of age) 

Complicated Urinary Tract Infections: and Pyelonephritis due to Escherichia coli.

NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. 
Adults 
Ciplet I.V. should be administered to adults by intravenous infusion over a period of 60 minutes at recommended dosages. Slow infusion of a dilute solution into a larger vein will minimize patient discomfort and reduce the risk of venous irritation. 
Method of administration 
Ciplet infusion should be checked visually prior to use. It must not be used if cloudy. Ciplet infusion should be administered by intravenously. For children, the infusion duration is 60 minutes. In adult patients, infusion time is 30 minutes for 200 mg Ciplet solution for infusion. 
Presentation: 
Availability: